Illumina launches whole-genome chips

Jan. 15, 2003 — Illumina Inc. (Nasdaq: ILMN, News, Web) has launched two biochips, including one that can analyze six human genomes, according to a news release.

Illumina’s new Sentrix BeadChips enable researchers to analyze expression profiles of an entire family of samples at one time on a microarray, compared with the traditional approach of analyzing a sample from a single person. The ability to analyze normal and diseased genes from several cancer patients, for example, brings researchers closer to the goal of personalized medicine, the release said.

The arrays are expected to be commercially available by mid-2004, following final field-testing with selected customers. San Diego-based Illumina, listed on Nasdaq, was trading Thursday afternoon at 8.35, down from 8.37 Wednesday.

POST A COMMENT

Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.